05.04.21

Novartis’ Sandoz Unit Confirms Late-Stage Clinical Development Plans for Proposed Biosimilar Aflibercept

Source: Novartis

03.31.21

NIH-Sponsored Trial Finds Eylea Reduced Vision-Threatening Complications by 68% After 2 Years in DR Patients

Source: Regeneron

10.30.20

Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases

Source: Ocumension Therapeutics

09.14.20

Novartis Reports Topline Results From the First Phase 3 Trial of Beovu Versus Aflibercept in DME Patients

Source: Novartis

07.27.20

New Novartis Analysis Examines Sustainable Fluid Control of Beovu Compared With Aflibercept

Source: Novartis

06.30.20

Samsung Bioepis Initiates Phase 3 Clinical Trial for SB15, Proposed Biosimilar to Eylea (Aflibercept)

Source: Samsung Bioepis

03.26.20

Regeneron to Extend Payment Terms for Eylea (Aflibercept) Injection

Source: American Academy of Ophthalmology

02.10.20

Regeneron: Eylea Reduced Risk of Developing Vision-Threatening Events by 75% After 2 Years in Patients With DR

Source: Regeneron Pharmaceuticals

12.10.19

Eylea Injection Prefilled Syringe Now Available

Source: Regeneron Pharmaceuticals

11.06.19

Biogen Gains Commercialization Rights to Anti-VEGF Biosimilar Candidates After Deal with Samsung Bioepis

Source: Samsung Bioepis

View more stories